FOSUN HEALTH Logo

Type 1 Diabetes Treatment

catalogue

Type 1 Diabetes Treatment

Type 1 Diabetes Treatment

Every honest conversation about treating Type 1 diabetes now has two halves. The first is insulin, which works, which is understood down to the unit, and which every patient in the world still depends on from the day of diagnosis. The second is newer and less settled: a structured integrative-medicine protocol — HIM — at Shenzhen Hengsheng Hospital, whose published interim analysis describes patients discontinuing insulin entirely. This page gives both halves in full, because a patient who is asked to consider the second without mastering the first is being sold something, and a patient dismissed from the second without reading it is being kept in the dark.

The foundation: replacing what the pancreas no longer makes

Everything in insulin therapy follows from one physiological fact: a healthy pancreas releases insulin two ways — a slow trickle around the clock, and a sharp burst with every meal. Replacement therefore has two parts, and every regimen in the world is a variation on them. The basal insulin covers the background; the bolus insulin covers the carbohydrates of each meal, dosed to what is actually eaten rather than fixed in advance. Getting this pairing right is what separates control from chaos, and structured education in carbohydrate counting is not an optional extra — it is half the treatment.

Insulin has been given for a century and the modern insulins are superb: long-acting basal analogues run flat for a day or more, rapid-acting bolus analogues start within minutes, and the safety margin between useful and dangerous doses has widened enormously. What has not changed is the discipline the treatment asks: glucose enters the conversation at every meal, every day, for life. That burden — not the injections themselves — is what patients most want relief from, and it is the honest measure of what any alternative protocol must beat.

The three ways insulin is delivered

Regimen How it works Who it suits
Multiple daily injections One or two long-acting basal injections a day, plus a rapid-acting bolus with each meal, counted in carbohydrates The default worldwide: no machinery, lowest cost, works for school, travel and work alike. Control depends on the counting discipline
Insulin pump A small worn device delivers rapid-acting insulin continuously, with meal boluses on demand Frequent hypoglycaemia, dawn phenomena, young children, or anyone whose injections cannot match their life's rhythm
Hybrid closed loop Pump and continuous glucose monitor talk to each other; an algorithm adjusts the background rate every few minutes The closest thing to an artificial pancreas in routine use; reduces both highs and lows. Still needs meal boluses and still needs the wearer

The regimens are stages of the same ladder rather than rival philosophies, and most patients move along it as life requires — a child may start on injections and reach the closed loop within a few years. None of them changes the underlying disease, which is the boundary all three share and the reason the next section exists.

Monitoring: the eyes of the whole treatment

Insulin dosed blind is insulin dosed dangerously. Finger-prick testing remains the universal fallback, but continuous glucose monitoring — a small sensor reading glucose every few minutes, with alarms for both directions — has become the standard of good care, and every serious regimen above assumes it. The numbers that matter across months are reviewed as patterns, not as single readings: the HbA1c, the three-month average, with individual targets set by age and circumstance rather than copied from a poster; the time in range; and the frequency and severity of lows.

Sick-day rules belong in the same paragraph because they are monitoring with consequences: any illness pushes glucose up and ketones follow, and a written plan — extra insulin, ketone testing, when to call, when to go to hospital — prevents more emergency admissions than any other single page in a patient's file. The plan is written before it is needed, which is the point of writing it here.

The HIM integrated-medicine protocol

The Chronic Disease Integrative Medicine Centre at Shenzhen Hengsheng Hospital treats Type 1 diabetes as an immune disease whose glucose consequences are secondary, on the argument that insulin replacement manages the sugar while doing nothing about the destruction causing it. The protocol — Holistic Integrative Medicine (HIM) — combines four lines of treatment that conventional endocrinology usually pursues separately or not at all.

  • Precision diagnosis. Mass-spectrometry platforms characterise the individual patient's immune pattern, on the premise that the autoimmune attack differs between patients and the counter-attack should be matched to it.
  • Immune regulation. Molecular nutrition and Chinese herbal medicine are used to modulate the immune response attacking the islets — the line of the protocol that addresses cause rather than consequence.
  • Metabolic repair. Acupuncture, herbal medicine and structured nutritional intervention aim to improve the environment in which residual beta cells survive and, where possible, recover function.
  • Precision monitoring. AI-assisted analysis of continuous glucose data and immune markers adjusts the protocol between visits; follow-up runs through tele-digital healthcare rather than requiring residence in China.

The inpatient phase is three to five days, during which the protocol is established, the insulin regimen is not abruptly abandoned but restructured, and the monitoring system is set up. Eligibility is assessed before travel from the records described on the diagnosis page — the antibody panel, the C-peptide and its trend, and the diagnosis date are the three items that decide whether the assessment proceeds.

The published interim results, read carefully

Here are the programme's numbers as published, with their frame attached. In a two-year clinical observation, 70 patients diagnosed with Type 1 diabetes were treated under the protocol. 24 of them — about one in three — discontinued insulin entirely, maintaining HbA1c below 7% with C-peptide testing showing recovery of islet function; the longest had been off insulin for 14 months at the time of publication, supported by dietary management and follow-up rather than exogenous insulin. The programme's own account attributes the results to immune blockade, intestinal mucosal repair and gut-microbiota reconstruction, and reports the pattern most clearly in patients diagnosed early with C-peptide above 0.5 ng/ml; patients with lower residual function are described as reducing insulin doses significantly after glucose stabilisation rather than discontinuing.

How to read this. These figures come from the hospital's own published interim analysis and are attributed as such throughout. Single-centre interim data is the weakest form of clinical evidence that still counts as evidence: the numbers are the numbers, but they have not yet been replicated independently, the follow-up is measured in months rather than years, and the durability of insulin independence is precisely what longer follow-up will establish. Insulin remains the standard of care, and no patient stops insulin except under structured monitoring after individual evaluation. What the results support is a consultation, not a conclusion.

The programme has drawn public comment from Academician Fan Daiming of the Chinese Academy of Engineering, a founder of integrative medicine in China, who described the results as challenging the traditional concept that Type 1 diabetes requires lifelong medication and as opening a new clinical treatment paradigm. His comment is quoted here because it is part of the public record, and with the same framing as everything else on this page: an evaluation of promise by a distinguished observer, not a guarantee of outcome for any individual.

The two emergencies every patient and family must know

Diabetic ketoacidosis develops when insulin is absent — missed doses, pump failure, or any serious illness — and presents as vomiting, abdominal pain, rapid breathing and fruity breath; it is treated as an emergency, with fluids, insulin and electrolytes, and the sick-day plan exists to intercept it early. Severe hypoglycaemia is the opposite failure: too much insulin for the glucose available, presenting as shakiness, sweating and confusion and, untreated, seizure and loss of consciousness. It is treated with fast sugar, and severe episodes with glucagon; the reason every patient carries fast sugar and every family knows the drill is that lows arrive faster than help.

Both emergencies are rarer and milder in well-monitored patients, which closes the loop on this page: the technology sections and the emergency sections are the same subject. Good monitoring is what makes aggressive insulin safe, and it is what makes any protocol transition safe too.

Frequently Asked Questions

Could I actually stop insulin under the HIM programme?

Possibly, if the evaluation supports it — and no one should promise it. The published results describe 24 of 70 patients who did, with the pattern strongest in early-diagnosed patients whose C-peptide was above 0.5 ng/ml. Eligibility is assessed from the antibody panel, C-peptide and diagnosis date before any travel; if the assessment places you outside the frame, the honest answer will say so. If you are inside it, the protocol proceeds without abruptly abandoning insulin, and any reduction happens under continuous glucose monitoring with ketone plans in place. The decision to reduce is made by data, repeatedly, not once.

What happens if the protocol does not work for me?

Then you are exactly where a good insulin patient is, with two additions. The insulin regimen you arrived with continues — it is never abandoned during the programme — and most participants see their glucose stability improve from the monitoring and nutrition work even where insulin reduction does not follow. The follow-up data continues regardless, because that is how interim evidence becomes better evidence. A failed attempt is a disappointment, not a step backwards.

Is this a cure?

Not in the way that word is usually meant, and the programme's own publications are careful about it. A cure would end the autoimmune disease for good with no monitoring. What is reported is insulin independence in a subset of patients: islet function recovered to a level sufficient for normal metabolic needs, maintained with diet and follow-up, over follow-up periods now stretching beyond a year in the longest cases. The honest framing is a treatment result worth pursuing, under evaluation, with durability still to be proven.

I have been on insulin for twenty years. Is the programme relevant to me?

Possibly, with expectations set accordingly. The reported pattern favours earlier diagnosis and higher C-peptide, and two decades of Type 1 diabetes usually means little residual islet function — which places most long-standing patients outside the frame in which discontinuation was reported. The evaluation will say where you sit. What remains relevant at any duration is the protocol's metabolic-repair and precision-monitoring work, which is aimed at stability and complications as much as at the insulin question itself.

Have the eligibility question answered in writing

Send the antibody panel, the most recent C-peptide, the HbA1c history, the current insulin regimen, and the age at diagnosis. The programme team will return a written opinion stating whether the HIM protocol's eligibility frame applies to you, what the realistic range of outcomes is for that position, and what the first inpatient week would involve — before any travel is booked.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*